Using Seroprevalence and Immunisation Coverage Data to Estimate the Global Burden of Congenital Rubella Syndrome, 1996-2010: A Systematic ReviewReport as inadecuate




Using Seroprevalence and Immunisation Coverage Data to Estimate the Global Burden of Congenital Rubella Syndrome, 1996-2010: A Systematic Review - Download this document for free, or read online. Document in PDF available to download.

Background

The burden of Congenital Rubella Syndrome CRS is typically underestimated in routine surveillance. Updated estimates are needed following the recent WHO position paper on rubella and recent GAVI initiatives, funding rubella vaccination in eligible countries. Previous estimates considered the year 1996 and only 78 developing countries.

Methods

We reviewed the literature to identify rubella seroprevalence studies conducted before countries introduced rubella-containing vaccination RCV. These data and the estimated vaccination coverage in the routine schedule and mass campaigns were incorporated in mathematical models to estimate the CRS incidence in 1996 and 2000–2010 for each country, region and globally.

Results

The estimated CRS decreased in the three regions Americas, Europe and Eastern Mediterranean which had introduced widespread RCV by 2010, reaching <2 per 100,000 live births the Americas and Europe and 25 95% CI 4–61 per 100,000 live births the Eastern Mediterranean. The estimated incidence in 2010 ranged from 90 95% CI: 46–195 in the Western Pacific, excluding China, to 116 95% CI: 56–235 and 121 95% CI: 31–238 per 100,000 live births in Africa and SE Asia respectively. Highest numbers of cases were predicted in Africa 39,000, 95% CI: 18,000–80,000 and SE Asia 49,000, 95% CI: 11,000–97,000. In 2010, 105,000 95% CI: 54,000–158,000 CRS cases were estimated globally, compared to 119,000 95% CI: 72,000–169,000 in 1996.

Conclusions

Whilst falling dramatically in the Americas, Europe and the Eastern Mediterranean after vaccination, the estimated CRS incidence remains high elsewhere. Well-conducted seroprevalence studies can help to improve the reliability of these estimates and monitor the impact of rubella vaccination.



Author: Emilia Vynnycky , Elisabeth J. Adams, Felicity T. Cutts, Susan E. Reef, Ann Marie Navar, Emily Simons, Lay-Myint Yoshida, David W

Source: http://plos.srce.hr/



DOWNLOAD PDF




Related documents